Kainova Therapeutics is a private biopharmaceutical company based in Montreal, Canada and Strasburg France. The company has a best-in-class GPCR discovery platform, BioSensALL, that is highly validated through multiple industry partnerships. The company is advancing multiple assets into the clinic, including a best-in-class anti-CCR8 antibody and a PAR2 antagonist.

Specialty

Solid tumors

Fund name

CTI LSF III

Position

Co-Lead

Board

Director

Investment Date

March 17, 2022

Exit Detail

Active

Initial Series Round

Series A

Investment Thesis

Kainova’s unique platform produced potential best-in-class assets against valuable GPCR targets, its lead assets demonstrated best-in-class data in the pre-clinical setting

Specialty

Fund name

Position

Board

Investment Date

Exit Detail

Initial Series Round

Investment Thesis

Related News

Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies

Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies

Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot, M.D., as Chief Medical Officer

Domain Therapeutics raises $42m Series A financing

Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study

Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening its unique portfolio of GPCR-targeting immunotherapies

Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening its unique portfolio of GPCR-targeting immunotherapies

Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study

Phone

Email

Address

Social Media